References
- Jackson D V, Jr, Bender R A. The clinical pharmacology of the vinca alkaloids epipodophyllotoxins, and waytansine. Clinical Pharmacology of Anti-Neoplastic Drugs, H M Pinedo. Elsevier/North Holland Biomedical Press, New York 1978
- Jackson D V. Vinca alkaloid chemotherapy. ISI Atlas of Science: Pharmacology 1987; 1: 124–128
- Jackson D V, Bender R A. Cytotoxic thresholds of vincristine in a murine and human leukemia cell line in vitro. Cancer Res. 1979; 39: 4346–4349
- Jackson D V, Sethi V S, Spurr C L, et al. Intravenous vincristine infusion: Phase I trial. Cancer 1981; 48: 2559–2564
- Jackson D V. Periwinkle alkaloids II: vincristine. Cancer Chemotherapy by Infusion, J J Lokich. Precept Press, Inc., Chicago 1987
- Jackson D V, Sethi V S, Spurr C L, et al. Pharmacokinetics of vincristine infusion. Cancer Treat Rep 1981; 65: 1043–1048
- Jackson D V, Paschold E H, Spurr C L, et al. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 1984; 53: 2601–2606
- Jackson D V, Muss H B, Richards F, et al. CCNU in combination chemotherapy for advanced histiological unfavorable non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1983; 11: 191–195
- Coltman C A, Dahlberg S, Jones S, et al. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: a twelve year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 1986; 5: 197
- Klimo P, Connors J M. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. An Intern Med 1985; 102: 596–602
- Armitage J O, Weisenburger D D, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma-rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 160–164
- Coleman M, Armitage J O, Gaynor J, et al. The COP+BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988; 25: 23–33
- Anderson H, Scarffe J H, Lambert M, et al. VAD chemotherapy—toxicity and efficacy—in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 1987; 5: 213–222